1 / 6
- Slide 1: OUTCOMES & HOME IRRIGATION | Hirschsprung Disease | Postoperative outcomes and home irrigation protocols for Hirschsprung disease management | Cincinnati Children's
- Slide 2: GCMD LIBRARY | HIRSCHSPRUNG DISEASE | OPTIMAL TIMING FOR SURGERY | Key Considerations | Infant age and weight | Disease severity and extent | Nutritional status | Presence of complications | Surgical expertise available | Clinical Decision Points | Early surgery (2-6 months) | Reduces enterocolitis risk | Improves long-term outcomes | Delayed surgery considerations | Severe prematurity | Significant comorbidities | Need for weight gain | Multidisciplinary Approach | Pediatric surgery | Gastroenterology | Nutrition support | Family counseling | Cincinnati Children's
- Slide 3: GCMD LIBRARY | HIRSCHSPRUNG DISEASE | BOTOX INJECTION DURING PULL-THROUGH | CURRENT EVIDENCE & PRACTICE | Does botulinum toxin injection during definitive pull-through improve outcomes in Hirschsprung disease? | BACKGROUND | • Hirschsprung disease requires removal of aganglionic bowel | • Pull-through procedures restore intestinal continuity | • Postoperative complications include constipation and incontinence | • Anal sphincter dysfunction may contribute to poor outcomes | BOTOX RATIONALE | • Temporary paralysis of internal anal sphincter | • Reduces sphincter spasm and outlet obstruction | • May improve stool passage in early postoperative period | • Theoretically reduces need for subsequent interventions | CURRENT EVIDENCE | • Limited high-quality studies available | • Some centers report improved short-term outcomes | • No consensus on optimal dosing or injection technique | • Long-term benefit remains unclear | • Randomized controlled trials needed | PRACTICE VARIATION | • Not universally adopted across pediatric surgery centers | • Some surgeons inject routinely during pull-through | • Others reserve for patients with postoperative complications | • Technique and dosing protocols vary widely | CONSIDERATIONS | • Safety profile generally favorable | • Temporary effect (3-4 months) | • Cost and availability factors | • Need for standardized outcome measures | • Patient selection criteria unclear | BOTTOM LINE | Current evidence does not definitively support routine botulinum toxin injection during Hirschsprung pull-through procedures. Practice remains variable and further research is needed to identify which patients may benefit. | Content developed by Cincinnati Children's Hospital Medical Center
- Slide 4: PRENATAL IMAGING IN CDH | Congenital Diaphragmatic Hernia | Predicting Postnatal Outcomes | ULTRASOUND | • Liver position (up/down) | • Lung-to-head ratio (LHR) | • Observed/expected LHR (O/E LHR) | MRI | • Total fetal lung volume (TFLV) | • Observed/expected TFLV (O/E TFLV) | • Liver herniation percentage | SEVERITY STRATIFICATION | Mild: O/E LHR >45%, O/E TFLV >35% | Moderate: O/E LHR 25-45%, O/E TFLV 25-35% | Severe: O/E LHR <25%, O/E TFLV <25% | FETAL INTERVENTION | Candidates: Severe cases with liver-up | Procedure: Fetoscopic endoluminal tracheal occlusion (FETO) | Goal: Promote lung growth before birth | Global Congenital Malformations Database
- Slide 5: Robotic Surgery vs. Laparoscopy | Learning Curve Comparison | Robotic Surgery | • Steeper initial learning curve | • Requires specialized training | • Console-based skills development | • Faster proficiency in complex cases | Laparoscopy | • Established training pathways | • Longer learning curve for advanced procedures | • Hand-eye coordination challenges | • More cases needed for mastery | Key Takeaway | Robotic platforms may accelerate skill acquisition for complex pediatric procedures despite higher initial training requirements | PEDIATRIC SURGERY INSIGHTS | Sponsored by GCMD
- Slide 6: GCMD | Subclavian Port Won't Flush | What's Your Next Move? | Assess patency | Check for mechanical issues | Consider fibrin sheath | Evaluate for thrombosis | Plan intervention if needed | GCMD Library | Advancing Pediatric Care
SCCOHT and HIPEC: Before or After Chemotherapy?
Topic overview
Educational content examining treatment sequencing for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), specifically addressing the timing of hyperthermic intraperitoneal chemotherapy (HIPEC) relative to systemic chemotherapy. Relevant for pediatric surgical oncologists managing this rare aggressive ovarian malignancy.
Comments